GlassScriptPhysician profile
Daniel J Hurley
NPI 1255739587
$4,464.58
in general payments reported to CMS, 2019-2025
50 companies · $881 in 2025
The $881 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,148 · 2022: $1,053 · 2023: $609 · 2024: $774 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $654.15 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $424.02 | 2021-2025 | |
| Novo Nordisk INC | $276.57 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $257.35 | 2021-2024 | Xarelto, Spravato |
| Pfizer INC. | $214.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $199.52 | 2021-2025 | Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $192.60 | 2023-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.45 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $167.93 | 2021-2024 | Mounjaro |
| Indivior INC. | $100.59 | 2021-2025 | Sublocade |
| Axsome Therapeutics, INC. | $100.55 | 2023-2025 | Auvelity, Sunosi |
| Orexo US, INC. | $100.04 | 2021-2025 | Zubsolv |
| Amarin Pharma, INC. | $93.66 | 2021-2023 | |
| Tolmar, INC. | $86.86 | 2024-2025 | Jatenzo |
| Bausch Health US, LLC | $82.62 | 2024-2025 | Aplenzin, Wellbutrin |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.